Patients With Type 2 Diabetes Prescribed SGLT2 Inhibitors Lose More Weight Than Those Prescribed GLP-1 Receptor Agonists

No important variations had been present in blood strain, blood sugar ranges, or kidney operate when evaluating each drugs amongst sufferers with kind 2 diabetes.

People with kind 2 diabetes who had been prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors misplaced considerably extra weight than those that had been prescribed glucagon-like peptide 1 (GLP-1) receptor agonists, in line with the findings of a brand new research.

Investigators aimed to judge the variations in weight reduction brought on by SGLT2 inhibitors and GLP-1 receptor agonists, each of that are continuously prescribed for kind 2 diabetes. Amongst 72 sufferers, people receiving SGLT2 inhibitors skilled a median weight lack of greater than 6 kilos, in comparison with a median of two.5 kilos amongst these receiving GLP-1 receptor agonists.

Each SGLT2 inhibitors and GLP-1 receptor agonists are indicated as second-line therapies for kind 2 diabetes after the usage of metformin, which can be prescribed to regulate blood sugar. The brand new research findings had been revealed in June within the Journal of the American Pharmacists Affiliation and characterize one of many first makes an attempt to match the two medicine, in line with the authors.

“Weight reduction is an advantageous high quality for diabetic drugs, as being obese is a standard attribute of the illness and might ultimately result in lowered insulin sensitivity,” stated lead writer Nicole Paolini Albanese, PharmD, a scientific affiliate professor within the College at Buffalo College of Pharmacy and Pharmaceutical Sciences, in a press launch. “With weight reduction, it’s attainable to regain insulin sensitivity, enhance glucose management, and scale back coronary heart threat components and comorbidities.”

Investigators analyzed medical information for sufferers with kind 2 diabetes who acquired both SGLT2 inhibitors or GLP-1 receptor agonists, along with different diabetes drugs, from 2012 to 2017. They measured weight reduction after 6 months of consecutive remedy, in addition to variations in blood strain, blood sugar ranges, and kidney operate.

Canagliflozin was probably the most generally prescribed SGLT2 inhibitor and liraglutide was probably the most generally prescribed GLP-1 receptor agonist, in line with the research. No important variations had been present in blood strain, blood sugar ranges, or kidney operate after use of the drugs. The findings recommend that SGLT2 inhibitors could also be extra protecting towards weight achieve brought on by different antidiabetic medicine than GLP-1 receptor agonists, Albanese stated within the press launch.

The findings additionally go towards earlier analysis, which has discovered that GLP-1 receptor agonists are the superior antidiabetic drug for weight reduction, in line with the research authors. They added that though the burden loss brought on by the drug is small, the research outcomes warrant bigger investigations that study the drugs’ impression on weight.

“These drugs at doses authorised for treating kind 2 diabetes will not be meant for weight reduction,” Albanese stated within the press launch. “Nonetheless, this could not discourage the dialogue of this potential profit, as even a small quantity of weight reduction is a novel benefit of those medicine, particularly when in comparison with potential weight achieve brought on by different therapy choices.”


Antidiabetic drug causes double the burden lack of competitor in kind 2 diabetes sufferers. Information launch. College at Buffalo. July 1, 2021. Accessed July 6, 2021.


Inter Reviewed is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

4 + 6 =

Back to top button